Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.68 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11172553 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1GAALMNATSHR | |
| SCHEMBL24704203 | 0.82 | NR4A2 (0.54) | NR4A2CREBBPKDM4EMAP2K1ALDH1A1 | |
| SCHEMBL30031033 | 0.81 | NR4A2 (1.00) | NR4A2CREBBPMAP2K1ALDH1A1NPSR1 | |
| SCHEMBL1093530 | 0.81 | NR4A2 (1.00) | NR4A2CREBBPMAP2K1ALDH1A1NPSR1 | |
| SCHEMBL10372680 | 0.80 | KDM4E (0.72) | NR4A2CREBBPKDM4EALDH1A1BRD4 | |
| SCHEMBL22230076 | 0.80 | PARP1 (0.53) | NR4A2CREBBPKDM4EALDH1A1GAA | |
| SCHEMBL29532188 | 0.80 | PARP1 (0.53) | NR4A2CREBBPKDM4EALDH1A1GAA | |
| SCHEMBL2918231 | 0.80 | PARP1 (0.54) | NR4A2CREBBPKDM4EMAP2K1AXL | |
| SCHEMBL2915155 | 0.80 | NR4A2 (0.51) | NR4A2CREBBPKDM4EMAP2K1AXL | |
| SCHEMBL2676355 | 0.80 | KDM4E (1.00) | NR4A2KDM4EALDH1A1PARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4041229-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| US-9173395-B2 | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| EP-2729007-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | Bayer Intellectual Property GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004652-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1954693-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | NEUROGEN CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-7326709-B2 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007062007-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20060217384-A1 | Bicyclic and tricyclic heteroaromatic compounds | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2006-09-28 | — | — | US | disclosed |
| US-7053093-B2 | Bicyclic and tricyclic hetroaromatic compounds | NEUROGEN CORPORATION (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030181455-A1 | Bicyclic and tricyclic hetroaromatic compounds | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-09-25 | — | — | US | disclosed |
| EP-1228069-B1 | BICYCLIC AND TRICYCLIC HETEROAROMATIC COMPOUNDS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6511987-B1 | Heterocyclic derivatives that bind to the benzodiazepine site of GABAA receptors for treatment of central nervous system disorders | NEUROGEN CORPORATION | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146546-A1 | Bicyclic and Tricyclic Heteroaromatic Compounds | GABBR1, GABBR2, GABRA4 | NR4A2 481/4885CREBBP 1542/4885KDM4E 2723/4885 |
| US-20030181455-A1 | Bicyclic and tricyclic hetroaromatic compounds | GABBR1, GABBR2, GABRA1 | NR4A2 444/4885CREBBP 1651/4885KDM4E 2660/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | NR4A2 1723/4885CREBBP 1004/4885KDM4E 1391/4885 |
| US-20140302987-A1 | USE OF SUBSTITUTED ISOQUINOLINONES, ISOQUINOLINDIONES, ISOQUINOLINTRIONES AND DIHYDROISOQUINOLINONES OR IN EACH CASE SALTS THEREOF AS ACTIVE AGENTS AGAINST ABIOTIC STRESS IN PLANTS | NQO1, NFE2, NDUFS1 | NR4A2 2056/4885CREBBP 2804/4885KDM4E 3457/4885 |
| US-20060217384-A1 | Bicyclic and tricyclic heteroaromatic compounds | GABBR1, GABBR2, GABRA4 | NR4A2 481/4885CREBBP 1542/4885KDM4E 2723/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | NR4A2 3505/4885CREBBP 2596/4885KDM4E 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.